Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma
F Tang, Y Lu, Y Ge, J Shang… - Journal of International …, 2020 - journals.sagepub.com
Objective To investigate the safety and efficacy of chimeric antigen receptor T (CAR-T) cell
infusion in patients with refractory multiple myeloma (MM). Methods Sixteen patients …
infusion in patients with refractory multiple myeloma (MM). Methods Sixteen patients …
Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma
Y Wang, J Cao, W Gu, M Shi, J Lan, Z Yan… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …
A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
H Zhang, M Liu, X Xiao, H Lv, Y Jiang, X Li… - Leukemia & …, 2022 - Taylor & Francis
Chimeric antigen receptor T (CAR-T) cells are a promising approach in hematopoietic
malignancies. We evaluated the safety and efficacy of a combination of humanized anti …
malignancies. We evaluated the safety and efficacy of a combination of humanized anti …
T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Therapies with novel mechanisms of action are needed for multiple myeloma (MM). B-cell
maturation antigen (BCMA) is expressed in most cases of MM. We conducted the first-in …
maturation antigen (BCMA) is expressed in most cases of MM. We conducted the first-in …
Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
H Li, L Zhao, Z Sun, Y Yao, L Li, J Wang, T Hua… - Frontiers in …, 2022 - frontiersin.org
Although chimeric antigen receptor T (CAR-T) cell therapy has been indicated to be effective
in treating relapsed or refractory multiple myeloma (R/R MM), severe hematological toxicity …
in treating relapsed or refractory multiple myeloma (R/R MM), severe hematological toxicity …
Correlation of cytokine release syndrome with prognosis after chimeric antigen receptor T cell therapy: analysis of 54 patients with relapsed or refractory multiple …
X Wang, L Zhao, J Wang, Y Yao, J Wang, S Ji… - Frontiers in …, 2022 - frontiersin.org
Although chimeric antigen receptor T (CAR-T) cell therapy has proven to be effective in
treating relapsed or refractory multiple myeloma (R/R MM), the severity of cytokine release …
treating relapsed or refractory multiple myeloma (R/R MM), the severity of cytokine release …
[HTML][HTML] Tandom autologous transplantation and combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for high risk MM: initial safety and …
X Shi, L Yan, J Shang, S Qu, L Kang, J Zhou, S Jin… - Blood, 2018 - Elsevier
Background: Multiple myeloma (MM) is an incurable plasma cell malignancies despite the
advent of numerously new drugs. Survival was poor particularly for high risk patients such as …
advent of numerously new drugs. Survival was poor particularly for high risk patients such as …
[HTML][HTML] Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
L Ding, Y Hu, H Huang - Stem cell investigation, 2021 - ncbi.nlm.nih.gov
Multiple myeloma (MM) is a malignant proliferative disease of plasma cells, which leads to
suppressed hematopoietic and osteolytic diseases. Despite the use of traditional …
suppressed hematopoietic and osteolytic diseases. Despite the use of traditional …
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
Z Yan, J Cao, H Cheng, J Qiao, H Zhang… - The Lancet …, 2019 - thelancet.com
Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell
therapy has been shown to have activity in patients with relapsed or refractory multiple …
therapy has been shown to have activity in patients with relapsed or refractory multiple …
The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma
D Duan, K Wang, C Wei, D Feng, Y Liu, Q He… - Frontiers in …, 2021 - frontiersin.org
Chimeric antigen receptor (CAR) technology has revolutionized cancer treatment,
particularly in malignant hematological tumors. Currently, the BCMA-targeted second …
particularly in malignant hematological tumors. Currently, the BCMA-targeted second …